Product Review

Product News: 11 2013

This month's Product News announces Valeant Pharmaceuticals International, Inc partnering with the National Coalition Against Domestic Violence to improve the lives of women. Also, this month features products recently approved by the United States Food and Drug Administration: Cimzia (certolizumab pegol) for the treatment of active psoriatic arthritis in adults, and Otrexup in a single-dose, diposable autoinjector, utiziling Vibex Medi-Jet technology for the treatment of severe, recalcitrant, disabling psoriasis in adults. La Roche-Posay releases 3 new antiaging products: Mela-D Deep Cleansing Brightening Foaming Cream, Redermic [R] Eyes, and Substiane [+] Serum.


 

Cimzia

UCB, Inc, obtains US Food and Drug Administration approval of Cimzia (certolizumab pegol), a tumor necrosis factor blocker for the treatment of active psoriatic arthritis in adults. Cimzia also is indicated in adults for the treatment of moderate to severe rheumatoid arthritis and to reduce signs and symptoms of moderately to severely active Crohn disease. For more information, visit www.cimzia.com.

La Roche-Posay Antiaging Products

La Roche-Posay Laboratoire Dermatologique releases 3 antiaging products: Mela-D Deep Cleansing Brightening Foaming Cream, Redermic [R] Eyes, and Substiane [+] Serum. The Mela-D product is a deep-cleansing and brightening formula with lipohy-droxy acid that combats dark spots and gives the skin a clean and smooth appearance. Redermic [R] Eyes combines 0.01% pure retinol with a retinol booster complex and caffeine to reduce crow’s-feet and dark circles to rejuvenate the eye area. Substiane [+] Serum increases the volume and elasticity of the skin. All products are physician dispensed or available in select drugstores and online. For more information, visit www.laroche-posay.us.

Otrexup

Antares Pharma Inc obtains US Food and Drug Administration approval of Otrexup (methotrexate), a folate analog metabolic inhibitor for the treatment of severe, recalcitrant, disabling psoriasis in adults who have not responded to other therapies. Otrexup is self-administered subcutaneously once weekly via an easy-to-use, single-dose, disposable autoinjector, which utilizes Vibex Medi-Jet technology. Otrexup also is indicated for adults with severe active rheumatoid arthritis and for children with active polyarticular juvenile idiopathic arthritis. For more information, visit www.otrexup.com.

Valeant Partners With National Coalition Against Domestic

Violence Valeant Pharmaceuticals International, Inc, announces a partnership with the National Coalition Against Domestic Violence (NCADV) to help improve the lives of women. Valeant pledges to donate a portion of sales from Medicis and Obagi products to support the initiatives of the NCADV. For more information, visit enddomesticviolence.valeant.com.

If you would like your product included in Product News, please e-mail a press release to Melissa Steiger at msteiger@frontlinemedcom.com.

Recommended Reading

Restrict Mohs surgery or risk drop in reimbursement
MDedge Dermatology
Mohs Appropriate Use Criteria
MDedge Dermatology
ASDS 2013 Roundup with Dr. Kavita Mariwalla
MDedge Dermatology
Stearic acid
MDedge Dermatology
Use lasers? Lawsuits soar when staff does the procedure
MDedge Dermatology
Pseudofolliculitis barbae – tips for patients
MDedge Dermatology
Cosmetic Corner: Dermatologists Weigh in on Shampoos and Conditioners
MDedge Dermatology
Novel PDT method proves superior for difficult AKs
MDedge Dermatology
Management of keloids draws on clinical wisdom
MDedge Dermatology
Superficial Plantar Fibromatosis
MDedge Dermatology